Group of systemic vasculitis with a strong association with anca. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposit...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for anti-neutrophil cytoplasmic antibody-associated vasculitis is limited primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This low prevalence restricts the number of systematic clinical studies, making comprehensive characterization of the condition challenging. Additionally, the absence of identified genetic factors further complicates understanding the disease.
To navigate your care effectively, seek a specialist in vasculitis or a rheumatologist with expertise in systemic autoimmune diseases. They can provide tailored management strategies for AAV. Additionally, consider participating in clinical trials to access cutting-edge therapies; you can find opportunities at ClinicalTrials.gov. For further support, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and guidance.
Currently, there is one orphan drug designated for AAV: Gabexate, which is still in development. Additionally, there are 107 active clinical trials exploring various aspects of this condition. For more details on these trials, you can visit ClinicalTrials.gov and search for 'anti-neutrophil cytoplasmic antibody-associated vasculitis' at https://clinicaltrials.gov/search?cond=anti-neutrophil%20cytoplasmic%20antibody-associated%20vasculitis. This research landscape offers hope for future treatment options.
Actionable guidance for navigating care for anti-neutrophil cytoplasmic antibody-associated vasculitis
To navigate your care effectively, seek a specialist in vasculitis or a rheumatologist with expertise in systemic autoimmune diseases. They can provide tailored management strategies for AAV. Additionally, consider participating in clinical trials to access cutting-edge therapies; you can find opportunities at ClinicalTrials.gov. For further support, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and guidance.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for anti-neutrophil cytoplasmic antibody-associated vasculitis is limited primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This low prevalence restricts the number of systematic clinical studies, making comprehensive characterization of the condition challenging. Additionally, the absence of identified genetic factors further complicates understanding the disease.
To navigate your care effectively, seek a specialist in vasculitis or a rheumatologist with expertise in systemic autoimmune diseases. They can provide tailored management strategies for AAV. Additionally, consider participating in clinical trials to access cutting-edge therapies; you can find opportunities at ClinicalTrials.gov. For further support, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and guidance.
Currently, there is one orphan drug designated for AAV: Gabexate, which is still in development. Additionally, there are 107 active clinical trials exploring various aspects of this condition. For more details on these trials, you can visit ClinicalTrials.gov and search for 'anti-neutrophil cytoplasmic antibody-associated vasculitis' at https://clinicaltrials.gov/search?cond=anti-neutrophil%20cytoplasmic%20antibody-associated%20vasculitis. This research landscape offers hope for future treatment options.
Actionable guidance for navigating care for anti-neutrophil cytoplasmic antibody-associated vasculitis
To navigate your care effectively, seek a specialist in vasculitis or a rheumatologist with expertise in systemic autoimmune diseases. They can provide tailored management strategies for AAV. Additionally, consider participating in clinical trials to access cutting-edge therapies; you can find opportunities at ClinicalTrials.gov. For further support, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and guidance.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for anti-neutrophil cytoplasmic antibody-associated vasculitis is limited primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This low prevalence restricts the number of systematic clinical studies, making comprehensive characterization of the condition challenging. Additionally, the absence of identified genetic factors further complicates understanding the disease.
To navigate your care effectively, seek a specialist in vasculitis or a rheumatologist with expertise in systemic autoimmune diseases. They can provide tailored management strategies for AAV. Additionally, consider participating in clinical trials to access cutting-edge therapies; you can find opportunities at ClinicalTrials.gov. For further support, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and guidance.
Currently, there is one orphan drug designated for AAV: Gabexate, which is still in development. Additionally, there are 107 active clinical trials exploring various aspects of this condition. For more details on these trials, you can visit ClinicalTrials.gov and search for 'anti-neutrophil cytoplasmic antibody-associated vasculitis' at https://clinicaltrials.gov/search?cond=anti-neutrophil%20cytoplasmic%20antibody-associated%20vasculitis. This research landscape offers hope for future treatment options.
Actionable guidance for navigating care for anti-neutrophil cytoplasmic antibody-associated vasculitis
To navigate your care effectively, seek a specialist in vasculitis or a rheumatologist with expertise in systemic autoimmune diseases. They can provide tailored management strategies for AAV. Additionally, consider participating in clinical trials to access cutting-edge therapies; you can find opportunities at ClinicalTrials.gov. For further support, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and guidance.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.